# Gee‐Chen Chang

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/gee-chen-chang/

## Facts

| Field | Value |
| --- | --- |
| Citations | 10,027 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 41 |
| i10-index | 98 |
| Last Known Institution | Chung Shan Medical University Hospital |
| OpenAlex ID | https://openalex.org/A5073440860 |
| ORCID iD | 0000-0002-1802-417X |
| Works | 238 |

## Researcher papers

- [Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-in-first-line/)
- [Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-with-or-without-tremelimumab-plus-platinum-etoposide-versus-platinum/)
- [Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study](https://scholariq.org/papers/osimertinib-for-pretreated-egfr-thr790met-positive-advanced-non-small-cell-lung/)
- [Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-erlotinib-in-patients-with-untreated-egfr-mutated-advanced-non/)
- [Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study](https://scholariq.org/papers/durvalumab-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung/)
- [Pretreatment Epidermal Growth Factor Receptor ( <i>EGFR</i> ) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pretreatment-epidermal-growth-factor-receptor-i-egfr-i-t790m-mutation-predicts/)
- [Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC](https://scholariq.org/papers/amivantamab-plus-lazertinib-in-previously-untreated-i-egfr-i-mutated-advanced/)
- [Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial](https://scholariq.org/papers/tepotinib-plus-gefitinib-in-patients-with-egfr-mutant-non-small-cell-lung-cancer/)
- [Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study](https://scholariq.org/papers/low-dose-ct-screening-among-never-smokers-with-or-without-a-family-history-of/)
- [Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer](https://scholariq.org/papers/phase-iii-keynote-789-study-of-pemetrexed-and-platinum-with-or-without/)
- [Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma](https://scholariq.org/papers/histological-transformation-after-acquired-resistance-to-the-third-generation/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)

## Researcher university

- [Chung Shan Medical University Hospital](https://scholariq.org/institutions/chung-shan-medical-university-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.